Key Details
Price
$2.17Annual EPS
-$3.63Annual ROE
-50.30%Beta
1.82Events Calendar
Next earnings date:
Mar 07, 2025Recent quarterly earnings:
Nov 12, 2024Recent annual earnings:
Mar 07, 2024Next ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
N/AAnalyst ratings
Recent major analysts updates
Market Data
Dividend
Profitability
Efficiency
Valuation
Liquidity
Cash Flow
Institutional Ownership
NMRA stock falls after its experimental depression treatment failed to meet the primary and secondary endpoints in the first of three late-stage studies.
LOS ANGELES--(BUSINESS WIRE)--Neumora Therapeutics, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights - NMRA.
CNBC's Angelica Peebles joins 'Power Lunch' to discuss Neumora's depression drug failing its trial results.
Neumora Therapeutics shares tumbled over 83% on Thursday after its experimental drug for major depressive disorder (MDD), navacaprant, failed to demonstrate significant benefits in the pivotal Phase 3 KOASTAL-1 study. The study, one of three replicate trials in Neumora's KOASTAL program, did not meet its primary endpoint of improvement in depressive symptoms as measured by the Montgomery-Åsberg Depression Rating Scale (MADRS) after six weeks.
Study did not demonstrate statistically significant improvement on primary endpoint of reduction in depressive symptoms as measured by MADRS total score compared to placebo
Neumora Therapeutics is set to release data from the phase 3 KOASTAL-1 study using Navacaprant for the treatment of patients with MDD by the end of 2024; other data in 2025. Navacaprant showed significant efficacy in a phase 2 study for MDD and is also being tested for bipolar depression, with phase 2 data expected in late 2025. Neumora has $341.3 million in cash, enough to fund operations until mid-2026, minimizing near-term dilution risk unless management opts otherwise.
Mizuho reiterated its bullish stance on biotech Neumora Therapeutics Inc. on Wednesday, and predicted a positive outcome when the company reports data from a late-stage trial of its treatment for major depressive disorder, or MDD, later this year.
Phase 3 data from KOASTAL-1 study of navacaprant in MDD expected around the end of 2024; KOASTAL-2 and KOASTAL-3 topline data expected in the first half of 2025
WATERTOWN, Mass., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of seven clinical and pre-clinical brain disease programs, today announced that the Company will participate in two investor conferences in November:
NMRA-511 is a highly potent and selective, best-in-class, antagonist of the vasopressin 1a receptor, which is known to play a role in regulation of aggression, stress and anxiety response
FAQ
- What is the primary business of Neumora Therapeutics Common Stock?
- What is the ticker symbol for Neumora Therapeutics Common Stock?
- Does Neumora Therapeutics Common Stock pay dividends?
- What sector is Neumora Therapeutics Common Stock in?
- What industry is Neumora Therapeutics Common Stock in?
- What country is Neumora Therapeutics Common Stock based in?
- When did Neumora Therapeutics Common Stock go public?
- Is Neumora Therapeutics Common Stock in the S&P 500?
- Is Neumora Therapeutics Common Stock in the NASDAQ 100?
- Is Neumora Therapeutics Common Stock in the Dow Jones?
- When was Neumora Therapeutics Common Stock's last earnings report?
- When does Neumora Therapeutics Common Stock report earnings?
- Should I buy Neumora Therapeutics Common Stock stock now?